---
title: "KOUZI today conducted a block trade at a discount, with 10 million shares traded and a transaction amount of 329 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254405804.md"
description: "On August 25th, KOUZI had a block trade of 10 million shares, with a transaction amount of 329 million yuan, accounting for 36.67% of the total transaction amount on that day. The transaction price was 32.92 yuan, a discount of 7.27% compared to the market closing price of 35.5 yuan"
datetime: "2025-08-25T09:30:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254405804.md)
  - [en](https://longbridge.com/en/news/254405804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254405804.md)
generator: "portal-rs"
---

# KOUZI today conducted a block trade at a discount, with 10 million shares traded and a transaction amount of 329 million yuan

On August 25th, KOUZI conducted a block trade of 10 million shares, with a transaction amount of 329 million yuan, accounting for 36.67% of the total transaction amount for the day. The transaction price was 32.92 yuan, a discount of 7.27% compared to the market closing price of 35.5 yuan

### Related Stocks

- [603589.CN](https://longbridge.com/en/quote/603589.CN.md)

## Related News & Research

- [Innovobot IRV joins Evara pre-seed financing round](https://longbridge.com/en/news/296527323.md)
- [13:49 ETVascarta Outlines Proposed Mechanistic Link Between VAS-101's (Vasceptor®) Vascular and Red Blood Cell Effects in Sickle Cell Disease](https://longbridge.com/en/news/296524035.md)
- [BEER: H1 2026 saw 22% sales volume growth, 15% revenue growth, and a €7M expansion investment](https://longbridge.com/en/news/296622535.md)
- [China NMPA clears InnoCare Phase III trial of mesutoclax-azacitidine in treatment-naive AML](https://longbridge.com/en/news/296164458.md)
- [09:15 ETSEC's Proposed E-Delivery Rule Signals a New Era in Customer Communications](https://longbridge.com/en/news/296361991.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**